Trading a MLYS straddle lets you take a pure volatility position on Mineralys Therapeutics Inc without committing to a direction. Mineralys Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate MLYS straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on MLYS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Mineralys Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the MLYS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the MLYS straddle is the cleanest expression of that view. Our scanner prices every MLYS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a MLYS straddle into a catalyst or short a MLYS straddle to harvest decay, the options straddle setups that matter are all in one place.
